FIND OUT MORE
Atrial Fibrillation (AF) is the most common type of arrhythmia and is a major risk factor for stroke, contributing to 1 in 5 strokes. It is estimated that in the UK alone, 1.4
million people have AF but almost 500,000 cases go undetected as symptoms are often difficult to detect.
However, with detection and appropriate treatment, the risk of stroke can be substantially reduced.
REQUEST A DEMONSTRATION
The Zensor™ device allows you to measure, analyse and report a patient’s heart rhythm for up to 14 days.
The only 3-lead continuous ECG and Wi-Fi enabled event monitor ensures optimal beat-by-beat trace clarity and can provide critical insight, particularly for paroxysmal atrial fibrillation, bradycardia and tachycardia detection.
With Zensor+ TM software, a comprehensive full disclosure report can be generated ready for analysis, review and consultation.
DOWNLOAD THE BROCHURE
Three-lead ECG provides enhanced cardiac visualisation
Continuous onboard recording for up to 14 days
Electrodes designed to minimise motion artefacts for improved data clarity
Patient-friendly device which is comfortable to wear results in high patient compliance
Wi-Fi enabled event detection
Direct access to full diagnostic ECG and event data reports through Zensor™ device software
The Zensor™ device is used with specifically designed motion artefact-reducing electrodes that optimise signal clarity. The patented electrodes overcome one of the key clinical challenges with traditional ECG and vital signs monitors – motion artefact.
The Zensor™ device has demonstrated an impressive >95% sensitivity for AF detection.
Zensor™ device assigned, attached to patient and activated
Optional Wi-Fi enabled event notification
Once the device is returned, patient data is uploaded direct to Zensor+™ Software
Access to high-quality, full disclosure ECG data and summary report